ArticlePharmacology research & perspectives2025

Improved Clinical Outcomes With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease: Real-World Evidence From an Italian Single-Center Study.

Nicola Perrotta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.